Key result
Monthly and biweekly alirocumab provide effective PCSK9 inhibition strategies for LDL-C lowering in ASCVD prevention.
Why the study?
Does monthly alirocumab compare favorably to biweekly alirocumab for LDL-cholesterol lowering in clinical practice?
Does monthly alirocumab compare favorably to biweekly alirocumab for LDL-cholesterol lowering in clinical practice?
Answers are grounded in this paper and cite their sources.
A letter discussing the clinical practice use of monthly versus biweekly alirocumab for LDL-cholesterol lowering.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Sbrana et al. (2026) studied this question. Monthly and biweekly alirocumab regimens serve as PCSK9 inhibitor strategies for LDL-cholesterol lowering in the prevention of atherosclerotic cardiovascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: